The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Polymyositis-related chronic graft-versus-host disease

Sep 26, 2018

In September 2018, findings from reported cases in graft-versus-host-disease (GvHD) associated polymyositis (PM) were published in Clinical Case reports. The authors aimed to review data from two reports of polymyositis-related GvHD in order to better understand this rare complication of allogeneic hematopoietic stem cell transplantations (allo-HSCT).

Case 1

  • 48-year-old woman with acute myeloid leukemia (AML), diagnosis in 2013
  • Complete remission (CR) after two courses of chemotherapy
  • The patient underwent allo-HSCT in February 2014 after reduced intensity conditioning
  • New symptoms after 10 months: limb weakness and mild dyspnea after walking without myalgia, skin rash, or obvious dysphagia

Case 2

  • 31-year-old woman with AML, diagnosis 20 months ago
  • CR was achieved with two courses of chemotherapy
  • Allo-HSCT after fifteen months after reduced intensity conditioning
  • Hospitalization because of limb weakness and myalgia for 5 months

Test results for Patients 1 and 2 (data is given as Patient 1 and 2)

  • CK (U/L): 2118 vs18
  • Lactate dehydrogenase (U/L): 528 vs241
  • Aspartate aminotransferase (U/L): 89 vs192
  • Alanine aminotransferase (U/L): 85 vs137
  • Myoglobin (ng/mL): 1057.90 vs3
  • CRP (mg/L): 0.2 vs6
  • Antinuclear antibodies: 1:100 vs1:320
  • Myositis autoantibody: negative in both patients
  • Thyroid glands: negative in both patients

Therapy

  • Patient 1
    • increased dosage of prednisone and cyclosporin A (CsA), but no significant result was seen
    • rituximab (100 mg) plus a low dose of intravenous immunoglobulin (IVIG, 5-10 g) weekly was applied for consecutive 6 weeks
    • the patient’s CK level became normal
  • Patient 2
    • oral prednisone and CsA did not improve the patient’s status
    • tacrolimus (3 mg QD) combined with oral methylprednisolone (40 mg QD) was implemented
    • Patient 2 had been followed up for over 1 year and she is in a good condition receiving tacrolimus at 3 mg with methylprednisolone at 12 mg daily

In summary, these case reports show that patients who underwent allo-HSCT can develop T cell-mediated immunologic muscle disorder which is similar to polymyositis with comparable clinical manifestations. Corticosteroids and immunosuppressants are feasible therapy options.

  1. Meng L. et al. Polymyositis as a manifestation of chronic graft-versus-host disease after allo-HSCT. Clin Case Rep.2018 Jul 12;6(9):1723-1726. DOI: 10.1002/ccr3.1709. eCollection 2018 Sep.